Drug Safety To Be Evaluated In Senate Health Committee Hearings
This article was originally published in The Tan Sheet
Executive Summary
The Senate Health Committee will convene March 1 and 3 to hold hearings on prescription drug safety issues
You may also be interested in...
FDA Drug Safety Board Keeps Oversight In House, Online
FDA's Drug Safety Oversight Board (DSB) will seek to address the agency's safety issues on an internal basis
Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says
Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18
FDA Postmarketing Safety Upgrades Gain Momentum In Congress
A new FDA drug safety office would have jurisdiction over OTC drug marketing under a proposal from Sen. Chris Dodd (D-Conn.)